Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.40 |
| ▸ | CNR1 | P21554 | 6/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14723926 | 0.79 | CNR1 (0.41) | CNR2CNR1HMGCRSMN1; SMN2NPC1 | |
| SCHEMBL1091042 | 0.79 | SMN1; SMN2 (0.38) | CNR2CNR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2609438 | 0.78 | ALDH1A1 (0.44) | CNR2SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL9947014 | 0.77 | CNR2 (0.39) | CNR2CNR1NPC1RAB9AALDH1A1 | |
| SCHEMBL18433548 | 0.76 | CNR2 (0.50) | CNR2CNR1ALDH1A1 | |
| SCHEMBL1013248 | 0.76 | CNR2 (0.38) | CNR2CNR1HMGCRALDH1A1 | |
| SCHEMBL9891487 | 0.76 | EGFR (0.42) | CNR2CNR1NPC1RAB9AALDH1A1 | |
| SCHEMBL12602876 | 0.75 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL9892807 | 0.74 | CNR2 (0.37) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL15121188 | 0.74 | CNR2 (0.45) | CNR2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | CNR2 3084/4885CNR1 2194/4885HMGCR 3868/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | CNR2 4544/4885CNR1 4436/4885HMGCR 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.